中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
17期
115-116
,共2页
重组人干扰素α1b%双歧三联活菌%小儿轮状病毒%肠炎
重組人榦擾素α1b%雙歧三聯活菌%小兒輪狀病毒%腸炎
중조인간우소α1b%쌍기삼련활균%소인륜상병독%장염
recombinant human interferon alPha 1b%bifid triPle viable%rotavirus%enteritis
目的:观察重组人干扰素α1b联合双歧三联活菌治疗小儿轮状病毒感染性肠炎的临床效果。方法根据就诊顺序将儿科2013年6月至2014年3月收治的92例患儿分为联合组和对照组,各46例。对照组采用常规治疗结合双歧三联活菌治疗,联合组在此基础上加用重组人干扰素α1b。结果联合组患儿的退热时间为(1.53±0.55)d、止泻时间为(2.08±0.55)d、住院时间为(3.2±1.2)d,均显著低于对照组的(2.36±0.69)d、(3.93±0.42)d、(5.5±1.5)d且差异显著( P<0.05);两组患儿的纠正脱水时间比较差异不显著( P>0.05)。治疗后第1,3天两组患儿的CD3+,CD4+,CD4+/CD8+较治疗前显著升高,CD8+则显著降低且差异显著( P<0.05),联合组的变化较对照组更显著( P<0.05)。联合组患儿治疗后的疗效分布显著优于对照组( P<0.05);联合组的总有效率为95.65%,显著高于对照组的80.43%( P<0.05)。结论重组人干扰素α1b联合双歧三联活菌治疗小儿轮状病毒感染性肠炎,可缩短治疗时间、增强患儿T细胞免疫能力,提高临床疗效。
目的:觀察重組人榦擾素α1b聯閤雙歧三聯活菌治療小兒輪狀病毒感染性腸炎的臨床效果。方法根據就診順序將兒科2013年6月至2014年3月收治的92例患兒分為聯閤組和對照組,各46例。對照組採用常規治療結閤雙歧三聯活菌治療,聯閤組在此基礎上加用重組人榦擾素α1b。結果聯閤組患兒的退熱時間為(1.53±0.55)d、止瀉時間為(2.08±0.55)d、住院時間為(3.2±1.2)d,均顯著低于對照組的(2.36±0.69)d、(3.93±0.42)d、(5.5±1.5)d且差異顯著( P<0.05);兩組患兒的糾正脫水時間比較差異不顯著( P>0.05)。治療後第1,3天兩組患兒的CD3+,CD4+,CD4+/CD8+較治療前顯著升高,CD8+則顯著降低且差異顯著( P<0.05),聯閤組的變化較對照組更顯著( P<0.05)。聯閤組患兒治療後的療效分佈顯著優于對照組( P<0.05);聯閤組的總有效率為95.65%,顯著高于對照組的80.43%( P<0.05)。結論重組人榦擾素α1b聯閤雙歧三聯活菌治療小兒輪狀病毒感染性腸炎,可縮短治療時間、增彊患兒T細胞免疫能力,提高臨床療效。
목적:관찰중조인간우소α1b연합쌍기삼련활균치료소인륜상병독감염성장염적림상효과。방법근거취진순서장인과2013년6월지2014년3월수치적92례환인분위연합조화대조조,각46례。대조조채용상규치료결합쌍기삼련활균치료,연합조재차기출상가용중조인간우소α1b。결과연합조환인적퇴열시간위(1.53±0.55)d、지사시간위(2.08±0.55)d、주원시간위(3.2±1.2)d,균현저저우대조조적(2.36±0.69)d、(3.93±0.42)d、(5.5±1.5)d차차이현저( P<0.05);량조환인적규정탈수시간비교차이불현저( P>0.05)。치료후제1,3천량조환인적CD3+,CD4+,CD4+/CD8+교치료전현저승고,CD8+칙현저강저차차이현저( P<0.05),연합조적변화교대조조경현저( P<0.05)。연합조환인치료후적료효분포현저우우대조조( P<0.05);연합조적총유효솔위95.65%,현저고우대조조적80.43%( P<0.05)。결론중조인간우소α1b연합쌍기삼련활균치료소인륜상병독감염성장염,가축단치료시간、증강환인T세포면역능력,제고림상료효。
Objective To observe the clinical effect of recombinant human interferon alPha 1b combined with Bifid TriPle Viable in the treatment of infantile rotavirus infectious enteritis. Methods 92 cases of rotavirus enteritis from June 2013 to March 2014 were selected and divided into combination grouP and control grouP according to visiting order,46 cases in each grouP. The control grouP used the conventional treatment combined with Bifid TriPle viable treatment;the combination grouP added with recombinant human interferon al-Pha 1b on the basis of the control. The ease situation,clinical curative effect and the related laboratory index of the two grouPs were comPared comParison. Results The fever abatement time was ( 1. 53 ± 0. 55 ) d,the antidiarrheal time and hosPitalization time were ( 2. 08 ± 0. 55 ) d and ( 3. 2 ± 1. 2 ) d in the combination grouP,which were significantly lower than ( 2. 36 ± 0. 69 ) d,( 3. 93 ± 0. 42 ) d, ( 5. 5 ± 1. 5 ) d in the control grouP,and the difference was significant ( P < 0. 05 );the difference of dehydration time of Patients in two grouPs were not significant ( P > 0. 05 ) . After 1 d,3 d treatment,the CD3 +,CD4 +,CD4 + /CD8 + of the two grouPs were significantly in-creased, while CD8 + decreased significantly and the difference was significant ( P < 0. 05 ) ,the increase of CD3 +,CD4 +, CD4 + /CD8+and the decrease of increased,CD8 + in the combination grouP were more significantly than the control grouP ( P < 0. 05 ) . Effect distri-bution of combination grouP after treatment was significantly better than that in the control grouP ( P < 0. 05 );the total efficiency of the combination grouP was 95. 65% which was significantly higher than 80. 43% in control grouP with significant difference ( P < 0. 05 ) . Conclusion Recombinant human interferon alPha 1b combined with Bifid TriPle Viable caPsule in treating infantile rotavirusinfectious enteritis has shortened treatment time,can increase T cell immunity in children,and imProve clinical curative effect.